Terbinafine in the treatment of cutaneous leishmaniasis: A pilot study
Terbinafine in the treatment of cutaneous leishmaniasis: A pilot study
复制标题
DOI：
10.1046/j.1365-4362.1997.00021.x
复制
发表时间：
1997-01-01
影响因子：
3.6
通讯作者：
Nauri, MM
中科院分区：
文献类型：
--
作者：
Bahamdan, KA;Tallab, TM;Nauri, MM
随机选择27名患者进行开放的先导研究，使用特比萘芬，剂量范围为250- 500mg /天，持续4周。纳入标准如下：(1)患者年龄在5岁及以上；(2)患者性别不限；(3)病变的数量和位置不限；(4)需进行寄生虫学确认；(5)患者此前未接受治疗；(6)排除妊娠或哺乳期患者；(7)需要患者或其父母的知情同意。寄生虫学诊断采用狭缝涂片技术，随后采用吉姆萨染色进行寄生虫鉴定。特比萘芬按年龄分两组给予两种不同剂量。各组分别为：1组，5 ~ 15岁，口服125 mg，每日2次，连用4周；2组，>15岁，250 mg口服，每日2次，连用4周。实验室血液检查包括全血细胞计数、肌酐、尿素和肝功能检查，在最初和2周和4周进行。通过评估入院后2周和4周时红斑、硬结和溃疡改善的百分比来评估临床反应。4周时报告最终评估：完全治愈，100%改善，无复发；部分治愈，改善大于或等于60%；失败,
Twenty-seven patients were randomly picked for an open pilot study using terbinafine with a dose range of 250-500 mg/day for 4 weeks. The inclusion criteria were as follows: (1) the patient had to be aged 5 years or older; (2) the patient could be of either sex; (3) any number or location of the lesions was allowed; (4) parasitologic confirmation was required; (5) the patient was allowed no previous treatment; (6) pregnant or lactating patients were excluded; (7) informed consent from the patient or his/her parents was required.The parasitologic diagnosis was carried out by a slit smear technique followed by a Giemsa stain for parasite identification. Terbinafine was given in two different doses to two groups sorted according to age. The groups were as follows: Group 1, 5-15 years, 125 mg orally twice daily for 4 weeks; Group 2, >15 years, 250 mg orally twice daily for 4 weeks. Laboratory blood investigations including complete blood count, creatinine, urea, and liver function tests were carried out initially and at 2 weeks and 4 weeks.Clinical response was evaluated by assessing the per cent of improvement of erythema, induration, and ulceration at 2 weeks and at 4 weeks after admission. The final assessment was reported at 4 weeks: complete cure, 100% improvement with no relapse; partial cure, greater than or equal to 60% improvement; failure,